Cortexyme, Inc. (CRTX)

Investigation 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cortexyme, Inc. ("Cortexyme" or "the Company") (NASDAQ: CRTX). The investigation concerns whether Cortexyme and certain of its officers and/or directors have violated federal securities laws.

 

On February 15, 2021, Cortexyme announced receipt of “a letter from the U.S. Food and Drug Administration (FDA) stating that a partial clinical hold has been placed on atuzaginstat (COR388) impacting the open-label extension (OLE) phase of the company’s ongoing Phase 2/3 study, the GAIN Trial.”  Cortexyme advised that, as a result of the partial clinical hold, “no new participants will be enrolled in the OLE and currently enrolled OLE participants will be discontinued.” According to the Company, “[t]he partial clinical hold was initiated following the review of hepatic adverse events in the atuzaginstat trial by the FDA.”  On this news, Cortexyme’s stock price fell $16.75 per share, or 35.29%, to close at $30.72 per share on February 16, 2021.

 

If you are aware of any facts relating to this investigation, or purchased Cortexyme shares, you can assist this investigation by visiting contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.